Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Details
Account Type
CFD Trading: MetaTrader 5
CFD Trading: MetaTrader 5
Investing: Web
Commission
0.1%
Trading schedule (UTC)
Open NowClosed NowCloses onOpening on
at
-
This shows the opening hours in your local time zone
(UTC)
Open an account and start investing with Metadoro now. Invite friends and get rewarded for their active trading. You can learn more about the affiliate program in your personal account.
Thank you for visiting metadoro.com. This website is managed by RHC Investments, which is authorised and regulated as an Investment Dealer by the Financial Services Commission of Mauritius with License number C115015381. Mauritius is not part of the European regulatory framework and is not in scope of (among others) the Markets in Financial Instruments Directive (MiFID) II.
By continuing you confirm that the decision is made independently and at your own exclusive initiative and that no solicitation or recommendation has been made by RHC Investments.
Create a NewsletterCreate a Newsletter
Customize your subscriptions the way you want!
Analytics
Get notified upon new posts
Select category
Price alerts
Discover timely market up-and-downs, pumps, etc.
Select category
Alert method
All categoriescategoriesAll instrumentsinstrumentssearchNothing found